Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.

Caputo, F., Skala, K., Mirijello, A., Ferrulli, A., Walter, H., Lesch, O., Addolorato, G., Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial, <<CNS DRUGS>>, 2014; 28 (8): 743-752. [doi:10.1007/s40263-014-0183-1] [http://hdl.handle.net/10807/60505]

Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Addolorato, Giovanni
2014

Abstract

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.
2014
Inglese
Caputo, F., Skala, K., Mirijello, A., Ferrulli, A., Walter, H., Lesch, O., Addolorato, G., Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial, <<CNS DRUGS>>, 2014; 28 (8): 743-752. [doi:10.1007/s40263-014-0183-1] [http://hdl.handle.net/10807/60505]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/60505
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 23
social impact